Abbott wins expanded indications for MitraClip

The FDA today said that it granted Abbott (NYSE:ABT) a new indication for its MitraClip system, expanding coverage of the device to patients with normal mitral valves with diminished left heart function. The indication expands upon the original approval, which the Chicago-area medical device maker won in 2013, clearing it for use in reducing mitral regurgitation in patients with mitral valve abnormalities whose risks for mitral valve surgery were prohibitive. With its new clearance, the MitraClip is cleared for use for patients with normal mitral valves who develop heart failure symptoms and moderate-to-severe or severe mitral regurgitation due to diminished left heart function despite treatment with optimal medical therapy. The agency said that the approval will allow a small percentage of patients with chronic heart conditions and moderate-to-severe or severe secondary mitral regurgitation to be candidates for treatment with the MitraClip alongside optimal medical therapy. The new approval came based on results from a 614-patient study of the device in patients with moderate-to-severe or severe secondary mitral regurgitation. Patients in the trial were treated with either optimized medication treatment and the MitraClip or medication only. Results from the trial indicated a 47% reduction in rehospitalization for patients in the MitraClip group over the control arm, with a two-year risk of death drop of 37% for MitraClip patients. “Expanding the approval of this devi...
Source: Mass Device - Category: Medical Devices Authors: Tags: Cardiac Implants Cardiovascular Featured Food & Drug Administration (FDA) Regulatory/Compliance Abbott Source Type: news